Skip to main content
. 2018 Dec 4;8(70):40288–40297. doi: 10.1039/c8ra07574c

Fig. 2. CLSM images of HepG2 cells (A) and HL-7702 cells (B) after treatment with FITC-labeled ss-MONs or FITC-labelled CM-ss-MONs for 3 h. Scale bars, 10 μm. Flow cytometry analysis of the uptake of 12.5 μg mL−1 FITC-labeled ss-MONs in HepG2 cells (C) and HL-7702 cells (D) after 3 h of exposure.

Fig. 2